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Abstract
This study examines the role of APE1/Ref-1 in the retina and its potential as a therapeutic target
for inhibiting retinal angiogenesis. APE1/Ref-1 expression was quantified by Western blot. The
role of APE1/Ref-1 redox function in endothelial cell in vitro angiogenesis was examined by
treating retinal vascular endothelial cells (RVECs) with APX3330, a small molecule inhibitor of
APE1/Ref-1 redox activity. In vitro methods included a proliferation assay, a transwell migration
assay, a Matrigel tube formation assay, and a Real Time Cell Analysis (RTCA) using the
xCELLigence System. In vivo functional studies of APE1/Ref-1 were carried out by treating very
low density lipoprotein (VLDL) receptor knockout mice (Vldlr−/−) with intravitreal injection of
APX3330, and subsequent measurement of retinal angiomatous proliferation (RAP)-like
neovascularization for one week. APE1/Ref-1 was highly expressed in the retina and in RVECs
and pericytes in mice. APX3330 (1 to 10 µM) inhibited proliferation, migration and tube
formation of RVECs in vitro in a dose-dependent manner. Vldlr−/− RVECs were more sensitive to
APX3330 than wild-type RVECs. In Vldlr−/− mice, a single intravitreal injection of APX3330 at
the onset of RAP-like neovascularization significantly reduced RAP-like neovascularization
development. APE1/Ref-1 is expressed in retinal vascular cells. APX3330 inhibits RVEC
angiogenesis in vitro and significantly reduces RAP-like neovascularization in Vldlr−/− mice.
These data support the conclusion that APE1/Ref-1 redox function is required for retinal
angiogenesis. Thus, APE1/Ref-1 may have potential as a therapeutic target for treating
neovascular age-related macular degeneration and other neovascular diseases.
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Neovascularization in the retina is a key pathology in several ocular diseases such as age-
related macular degeneration (AMD), diabetic retinopathy (DR), and retinopathy of
prematurity (ROP). It is a primary cause of severe vision loss. The most advanced anti-
angiogenic treatments, including anti-VEGF therapy, are effective, but only improve vision
significantly in 25–40% patients (Hernandez-Pastor et al., 2008, Rosenfeld et al., 2006).
While VEGF is a dominant factor in pathological neovacularization, retinal
neovascularization has a complex etiology, possibly including multiple genetic and non-
genetic factors. These factors include expression and/or activities of complement, integrin,
platelet-derived growth factor, inflammatory cytokines, oxidants, and macrophages, which
play important roles in various stages of retinal neovascularization (Klein, 2007). Clinical
management of retinal neovascularization remains a great challenge, and novel treatment
strategies that target multiple components of the angiogenesis cascade hold great potential to
improve clinical outcomes.
APE1/Ref-1 (also known as Ref-1, HAP1, hAPE, APE or APEX) is a multi-functional
protein with apurinic/apyrimidinic endonuclease activity, encoded by an evolutionarily
conserved C-terminal domain, and reduction-oxidation (redox) activity, encoded by a
functionally-independent N-terminal domain unique to mammalian members of this protein
family (Tell et al., 2005, Xanthoudakis et al., 1994). APE1/Ref-1 redox activity stimulates
numerous transcription factors that are involved in cancer promotion and progression, such
as PAX, HIF-1α and NFκB, AP-1 (Fos/Jun), HLF, p53, and others (Evans et al., 2000,
Fishel and Kelley, 2007, Tell et al., 2005). Several of these transcription factors also play
roles in angiogenesis (i.e., HIF-1α (Carmeliet et al., 1998, Gariano and Gardner, 2005),
NFκB (Huang et al., 2001, Huang et al., 2000, Yoshida et al., 1999), and AP-1 (Tischer et
al., 1991); for review see (Maulik, 2002). In addition, a high level of APE1/Ref-1 expression
is associated with more active angiogenesis and chemotherapy resistance in tumors
(Bicknell and Harris, 2004, Bilton and Booker, 2003). Selective inhibition of the APE1/
Ref-1 redox function by APX3330 (E3330/BQP) inhibits the growth of tumor endothelium
and endothelial progenitor cells (Zou et al., 2008). Our recent report that APX3330
significantly attenuates proliferation and tube formation of retinal vascular endothelial cells
(RVECs) suggests that APE1/Ref-1 could play a role in retinal angiogenesis (Luo et al.,
2008).
This study explores the role of the APE1/Ref-1 redox function during retinal angiogenesis in
vitro in RVEC cells and in vivo in Vldlr−/− mice. The Vldlr−/− mouse develops spontaneous
age-related RAP-like neovascularization evolving from the retina which mimics the
essential histological and angiographic characteristics of retinal angiomatous proliferation
(RAP), a subtype of neovascular AMD (Heckenlively et al., 2003, Hu et al., 2008, Li et al.,
2007). The results show that APX3330 potently inhibits the growth of RVEC in vitro and
significantly reduces RAP-like neovascularization in Vldlr−/− mice, suggesting that APE/
Ref-1 is required for retinal angiogenesis in the mouse. Therefore, inhibiting the redox
function of APE1/Ref-1 may offer a novel approach to treat retinal angiogenesis.
MATERIALS AND METHODS
Experimental animals
All animals used in the study were maintained and treated with strict adherence to the
guidelines for animal care and experimentation prepared by the Association for Research in
Vision and Ophthalmology and approved by the Indiana University Animal Care and Use
Committee. Breeding pairs of mutant mice with targeted deletion of the Vldlr gene (B6;
129S7-Vldlrtm1Her/J; Vldlr−/−) (Frykman et al., 1995) were obtained from the Jackson
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Laboratory (Bar Harbor, Maine, USA). Breeding pairs of an ImmortoMouse® transgenic
line expressing a temperature-sensitive SV40 large T antigen were obtained from the
Charles River Laboratories (Wilmington, MA). Both wild-type (C57BL/6J; +/+) and
Vldlr−/− mice were crossbred with the transgenic ImmortoMouse, respectively. Cells
isolated from the littermates produced from these crosses can be immortalized by turning on
the SV40 gene in vitro. All offspring were subjects for PCR genotype confirmation of SV40,
wild-type Vldlr, and Vldlr knockout genes.
Matrigel Tube Formation Assay
Early passage (2–4 days) of human umbilical cord blood-derived endothelial colony forming
cells (ECFCs) were starved in EBM2 (Lonza, Walkersville, MD) + 0.5% FBS (Hyclone,
Logan, UT) for 16 hours. ECFCs were detached with trypsin EDTA (Invitrogen, Carlsbad,
CA) and a viable cell count obtained via trypan blue exclusion. Cells were suspended in
EBM2 + 0.5% FBS with vehicle only or varying concentrations of APX3330 dissolved in
DMSO or Avastin® (Genentech, San Francisco, CA). DMSO/vehicle controls were
routinely included in the assay. 7500 cells per well were plated into 96 well tissue culture
plates precoated with matrigel. Each condition was plated in triplicate. Plates were incubated
at 37°C in a 5% CO2, humidified incubator and examined after 6–8 hours for tube
formation. Low magnification images were captured to quantify the total number of closed
network units formed per well. The same assay was also performed in RVECs isolated from
wild-type and Vldlr−/− mice (Nagata et al., 2003).
TUNEL Assay
TdT mediated dUTP-fluorescein nick end-labeling (TUNEL) assay which allows us to
determine the percentage of cells undergoing apoptosis. The reactions were performed
following the manufacture’s protocol (Roche, Indianapolis, IN). Cells were treated with
various concentrations of APX3330 for 24 hours. A 100 µM H2O2 group was included to
serve as a positive control. Random fields of cells are photographed under phase microscopy
and scored as percent positive cells for the terminal transferase labeling reaction.
RVEC primary culture
Mouse RVECs and retinal pericytes (RPCs) were isolated as described before with
modifications (Su et al., 2003). Briefly, retinal tissues from young adult wild-type and
Vldlr−/− mice carrying a SV40 transgene were digested with collagenase type I
(Worthington, Lakewood, NJ) in DMEM. The dissociated cells were incubated with sheep
anti-rat magnetic beads (Dynal Biotech, Lake Success, NY) pre-coated with a rat anti-mouse
PECAM-1 monoclonal antibody (BD Biosceinces, San Jose, CA) for affinity binding of
RVECs. Bead-bound cells were seeded in a 24-well plate pre-coated with fibronectin (BD
Biosciences, San Jose, CA) in an endothelial cell growth medium (EBM/EGM-2MV,
Cambrex). Detailed characterization of these cells (>95% endothelial cells) are described in
our recent publication (Jiang et al., 2009). A similar protocol was used to isolate retinal
pericyte but using anti-mouse α-SMA antibody to label the magnetic beads, Cells were
maintained in culture at 33°C with interferon to turn on the SV40 gene, but were assayed
under ordinary conditions at 37°C in the absence of interferon.
Western blot
Whole cell/tissue extract were prepared using RIPA buffer supplemented with protease
inhibitor cocktail. The protein extract were separated by 10% SDS-PAGE electrophoresis,
and transferred to a nitrocellulose membrane. After blocking in 5% non-fat milk in TBS/T
buffer, blots were probed with an anti-APE1/Ref-1 monoclonal antibody (Novus
Biologicals) and an anti-tubuline monoclonal antibody (1:400 for both) at 4°C overnight.
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Blots were then incubated with HRP-conjugated secondary antibodies (Amersham
Pharmacia, Arlington Heights, IL) at room temperature for 1 hour, and were visualized by
enhanced chemiluminescence (ECL; PerkinElmer).
Cell proliferation assay
RVECs were starved in basal medium supplemented with 0.2% FBS (EBM) at 37°C
overnight. After trypsinization, cells were resuspended in basal medium, and seeded at 2,000
cells/well in 96-well plates. APX3330 at various concentrations was added three hours later.
After 48 hours incubation at 37°C, the total number of cells was assayed by using the
CellTiter 96® AQueous One Solution (Promega Corporation, Madison, WI). The
absorbance value at 490 nm was read by a microplate reader (GENios Pro, Tecan Trading
AG, Switzerland) after 1 hour incubation. Experiments were performed in 5 to 6 wells per
group each time and repeated three times.
Migration assay
Migration was performed using modified Boyden chambers containing polycarbonate
membrane (Transwell, 5.0 µm pore size; Costar, Cambridge, MA) with slight modification
(Cai et al., 2000). Wild-type and Vldlr−/− RVECs at the same confluence were starved in
basal medium overnight and then seeded at 5 × 103 cells/well into Transwell plates coated
with fibronectin (10 µg/ml). Basal medium supplemented with 10 ng/ml bFGF, with or
without APX3330 at different concentrations were added to the lower chamber and
incubated at 37°C for 16 hours. Viable cells were stained with the CellTracker™ Green
BODIPY®, fixed in 1% PFA, and counterstained with DAPI. The upper surface of the
Transwell member was scraped with a cotton swab to remove un-migrating cells. Seven
images of migrating cells were taken randomly from each membrane with a 10× objective.
The average number of nuclei in each image was determined. The experiment was
performed in triplicate.
Real-Time Cell Impedance Analysis
Dynamic cellular biology was monitored using Real-Time Cell Analyzer single-plate
(RTCA SP) Instrument, xCELLigence System (Roche Applied Science, Mannheim,
Germany). The system monitors cellular events in real time measuring electrical impedance
across interdigitated micro-electrode integrated on the bottom of tissue culture E-Plates. The
impedance measurement provides quantitative information about the biological status of the
cells, including cell number, viability, and morphology. A dimensionless parameter called
Cell Index (CI) is derived as a relative change in measured electrical impedance to reflect
the integrated cellular status in the culture. For experiments, both wild-type and Vldlr−/−
RVEC were starved in EBM/0.2% FBS overnight before being seeded on an E-Plate 96.
Two hours after seeding, different concentrations of various compounds (APX3330,
Avastin®, or Lucentis®) were added in tetraplicate. Dynamic CI values were monitored in
30-minute intervals from the time of plating until the end of the experiment (77 hours). CI
values were calculated and plotted on the graph. Standard deviation of tetraplicates of wells
for the two types cells with different treatments were analyzed with the RTCA Software.
Intravitreal treatment
Intravitreal treatment was performed Vldlr−/− mice at P14 after anaesthetization. Each
animal received a single intravitreal injection of 1 µl volume of BSS® (balanced saline
solution, Alcon Laboratories, Fort Worth, Texas) as a vehicle control and the fellow eye
received 1 µl of 200 µM APX3330. The target concentration of APX3330 in the retina is
approximately 20 µM. An Avastin® (Genentech, South San Francisco, California) treatment
group was included for comparison.
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A conjugate of isolectin IB4 from Griffonia simplicifolia (isolectin IB4 Alexa Fluor 488,
Invitrogen) was used for retinal blood vessel labeling in whole flat mounts. One week after
intravitreal treatment, the eyes were harvested and fixed in 1% PFA at 4°C overnight.
Retinas were separated, with 4–6 radial cuts to flatten the retina. After blocking, the entire
neural retina was incubated in a 1:200 diluted isolectin solution containing 3% donkey
serum for 2 days at 4°C, washed with PBS, and mounted with a ProLong Gold antifade
reagent (Invitrogen). Retinal images focusing on the subretinal space were photographed
under an inverted fluorescence microscope at 10× magnification (Leica DM IRB, Leica
Microsystems Inc., Bannockburn, IL). A whole retinal montage was used to quantify the
total number of RAP-like neovascularization with masked label.
Statistical analysis
All the statistical analyses were performed using SPSS11.0 (SPSS, Chicago, IL). Data are
presented as mean ± SD. Differences were assessed using one-way or two way analysis of
variance (ANOVA) or the student t test. A value of p < 0.05 is considered statistically
significant.
RESULTS
APX3330 inhibits endothelial cell tube formation
Previous studies suggest that APX3330 inhibits downstream functions of HIF-1α in
angiogenesis (Luo et al., 2008). Therefore we examined the effect of APX3330 and
combined effect of APX3330 and Avastin®, a known anti-angiogenic compound on
Matrigel tube formation assay using human ECFCs. As shown in Figure 1, APX3330
impaired the ability of these cells to form tubules. At 10 µM, APX3330 reduced tube
formation by 61%, while Avastin® (500 µg/ml) had little effect on tube formation.
However, the combination of these two agents at these doses completely inhibited tube
formation. A similar result was observed with Avastin® (500 µg/ml) and a lower dose of 5
µM APX3330. These data suggest that the effects of APX3330 and Avastin® on endothelial
cell tube formation are at least additive or maybe even synergistic.
APX3330 does not induce apoptosis
APX3330 could reduce the amount of endothelial cell tube formation by inducing cell death.
Therefore, TdT mediated dUTP-fluorescein nick end-labeling (TUNEL) assay was
performed to quantify cell death of ECFCs in the presence and absence of APX3330. Figure
2 shows that 24 hour exposure to APX3330 does not induce apoptosis, but exposure to
H2O2, a positive control, does induce apoptosis under the same condition tested. These data
are consistent with the possibility that the effect of APX3330 on endothelial cell tube
formation is mediated by inhibition of APE1/Ref-1 redox activity. A similar result was
obtained previously (Tell et al., 2005).
Expression of APE1/Ref-1 in the retina and retinal vascular cells
Previous studies reported that APE1/Ref-1 is expressed in the developing retina (Chiarini et
al., 2000, Chiarini and Linden, 2000). Here, the expression of APE1/Ref-1 in retinal
vascular cells was examined for the first time. Western blot analysis indicated APE1/Ref-1
protein was abundantly expressed in the adult neural retina, as well as in purified RVECs
and retinal pericytes (RPCs) (Figure 3). It also revealed that levels of APE1/Ref-1 protein
were comparable in retinal tissues and vascular cells from wild-type and Vldlr−/− mice
(Figure 3). No genotypic difference was noticed.
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APX3330 inhibits retinal endothelial cell proliferation
To test the specific effect of APX3330 on retinal vascular cells, a serious of in vitro assays
was carried out using magnetic beads-purified RVECs. We have previously showed that
APX3330 inhibits proliferation of wild-type RVECs in vitro (Luo et al., 2008), which
suggests that it is likely to inhibit angiogenesis in vivo. In the present study, we have found
that APX3330 inhibited the proliferation of not only wild-type but also Vldlr−/− RVECs
(Figure 4A). This was associated with a slightly higher efficacy in Vldlr−/− RVECs
(61.58±7.66%) than that in wild-type RVECS (84.15±9.23%). Because Vldlr−/− RVECs
grow at a much faster rate (Jiang et al., 2009), Vldlr−/− RVECs are more sensitive to
APX3330 than wild-type RVECs.
APX3330 inhibits retinal endothelial cell migration
Endothelial cell migration is essential for angiogenesis. Therefore, the effect of APX3330 on
migration of wild-type and Vldlr−/− RVECs was examined using a dual chamber transwell
assay. Cells were seeded in the upper chamber and basic fibroblast growth factor (bFGF) (10
ng/ml) was added to the lower chamber as a chemoattractant. In the absence of APX3330,
migrating Vldlr−/− RVECs (311.93±4.75) were more abundant than migrating wild-type
RVECs (228.28±7.07) (Figure 4B; p < 0.01), as reported previously (Jiang et al., 2009).
Furthermore, APX3330 (5 µM) significantly inhibited migration of RVECs, reducing the
number of migrating wild-type RVECs by 69% to 70.21±17.68 per field (p < 0.01) and
reducing the number of migrating Vldlr−/− RVECs by 90% to 34.71±3.23. Similar results
were obtained when cells were treated with 10 and 20 µM APX3330.
APX3330 inhibits retinal endothelial cell angiogenesis in vitro
Results presented in Figures 1 show that APX3330 inhibits human ECFC tube formation in
a dose-dependent manner. Here, we show that despite a much higher basal level of tube
formation in Vldlr−/− RVECs than wild-type RVECs, addition of APX3330 was still able to
inhibit such profound ability to form capillary-like structures dose-dependently (Figure 5).
The inhibitory effects of APX3330 on Vldlr−/− RVEC tube formation was already
significant (p < 0.05) at 1 µM concentration (Figure 5C) and reached 78% reduction at 20
µM APX3330 (p < 0.01; Figure 5B, C). The much enhanced tube formation in Vldlr−/−
RVECs is consistent with our previous report (Jiang et al., 2009).
APX3330 reduces CI of retinal endothelial cells
A Real-Time Cell Analyzer (RTCA) was also used to monitor dynamic changes in the
properties of retinal endothelial cells during prolonged exposure to APX3330. RTCA
evaluates the ionic environment at an electrode/solution interface in a cell culture. RTCA
output is a dimensionless parameter called Cell Index (CI), which integrates information on
cell viability, number, morphology, and adhesion. RTCA assays were initiated by seeding
wild-type and Vldlr−/− RVECs on an E-Plate 96 at the same density. APX3330 was added at
5, 10 and 20 µM 2 h after seeding and CI values were monitored at 30-minute intervals for
72 h. As shown in Figures 7A and 7B, APX3330 reduced CI values in wild-type and
Vldlr−/− RVECs in a dose- and time-dependent manner. The effect was statistically
significant in all three doses in both genotype RVECs (p < 0.05). Despite a significant
upsurge of the growth curve, the response of Vldlr−/− RVECs to APX3330 was more
dramatic than that of corresponding wild-type RVECs. This is consistent with our above
findings of the more potent effects of APX3330 on Vldlr−/− RVEC proliferation (Figure 6A)
and migration than the wild-type (Figure 6B). These in vitro results indicate that activated
endothelial cells are more sensitive to APX3330 treatment. Such selective effect would be
favorable for future therapeutic usage if proven.
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Lucentis® and Avastin® are anti-VEGF antibodies used to treat AMD in the clinic.
Therefore, the effect of Lucentis® and Avastin® on CI values of RVECs was also measured
using RTCA. In contrast to APX3330, Lucentis® (20 µg/ml and 100 µg/ml) did not reduce
CI values of wild-type or Vldlr−/− RVECs (Figure 6C and D). Avastin® significantly
reduced CI values of wild-type and Vldlr−/− RVECs at a high dose (200 µg/ml, p < 0.05) but
not at a lower dose (50 µg/ml (Figure 6, E and F) and Vldlr−/− RVECs were less sensitive to
Avastin® than wild-type RVECs. A much higher dose of Avastin® was required to reduce
CI values to the same extent as APX3330 (200 µg/ml Avastin® versus 5–10 µM APX3330).
APX3330 inhibits RAP-like neovascularization in Vldlr−/− mice
As shown in Figures 4–6, APX3330 strongly inhibits proliferation, migration and tube
formation of Vldlr−/− RVECs, and the effects of APX3330 are more potent in Vldlr−/− than
in wild-type RVECs. To extend these observations to an in vivo model, Vldlr−/− mice at P14
were dosed with 1 µl of 200 µm APX3330 or 25 µg Avastin® (control) by intravitreal
injection. The final concentration of APX3330 was equivalent to approximately 20 µM in
the retina. To minimize individual variation, one eye was injected with APX3330 or
Avastin®, while the fellow eye of the same mouse was injected with vehicle control (BSS).
One week after the injection, RAP-like neovascularization were quantified in the whole
mount retina stained with isolectin-FITC. In 17/20 mice (85%), the number of RAP-like
neovascularization was lower in the APX3330-treated eye than in the untreated eye of the
same animal (Figure 7C) with 75% of treated eyes showing > 20% reduction in RAP-like
neovascularization (p = 0.000772 in paired t-test). In contrast, Avastin® only reduced RAP-
like neovascularization in 1/7 mice (Figure 7D) and the overall results were not significantly
different.
DISCUSSION
This study shows that APE1/Ref-1 is highly expressed in the retina, choroid/RPE, and in
RVECs and RPCs from the mouse and provides evidence that APE1/Ref-1 redox activity is
required for efficient retinal endothelial cell proliferation, migration and tube formation.
Furthermore, Vldlr−/− RVECs not only responded in vitro to APX3330, a selective inhibitor
of APE1/Ref-1 redox activity, but were more sensitive to APX3330 than wild-type RVECs.
The Vldlr−/− mouse model was used to provide complementary in vivo data suggesting that
APE1/Ref-1 plays a role in retinal angiogenesis in the mouse. In particular, a single
intravitreal injection of APX3330 at the onset of RAP-like neovascularization significantly
reduced the total number of RAP-like neovascularization in Vldlr−/− mice after one week.
APE1/Ref-1 in the retina
APE1/Ref-1 expression in the retina has been reported previously (Chiarini et al., 2000,
Chiarini and Linden, 2000). For example, Chiarini and colleagues localized the expression
of APE1/Ref-1 to ganglion cells and inner nuclear layers of the retina, with relatively less
staining in the outer nuclear layer. Staining of the photoreceptors was more intense than in
the neuroblastic layer of younger rats. In tissue from both P27 and P45 rats the pattern of
immunoreactivity for APE1/Ref-1 was similar to that at P13 (Chiarini et al., 2000).
Expression of APE1/Ref-1 is lower in the retina following ischemia/reperfusion injury, and
intravitroues bFGF can upregulate the expression of APE1/Ref-1 (Wang et al., 2007). Our
findings show strong expression of APE1/Ref-1 in the retina of adult wild-type and Vldlr−/−
mice. A high level of APE1/Ref-1 protein was also detected in purified RVECs and
pericytes, consistent with an important biological role for APE1/Ref-1 in retinal
vascularization, as discussed below.
Jiang et al. Page 7













APE1/Ref-1 as a target for anti-angiogenesis treatment in retinal neovascular disorders
Previous studies using APX3330 suggested that APE1/Ref-1 redox activity is required for in
vitro proliferation and tube formation by RVECs (Luo et al., 2008) and for in vitro growth
of pancreatic cancer-associated endothelial cells (Zou et al., 2008). This study confirms the
earlier finding that APX3330 inhibits proliferation of murine RVECs in vitro. However, an
important novel finding of this study is that APX3330 has more potent growth inhibitory
effects in vitro on Vldlr−/− RVECs, which are activated with respect to angiogenic function
and activity, relative to wild-type RVECs (Jiang et al., 2009). Although the exact
mechanism for this effect is not known, it could be that activated endothelial cells are more
dependent on the APE1/Ref-1 redox function than not activated endothelial cells. Western
blot analysis suggests a similar level of APE1/Ref-1 protein in wild-type and Vldlr−/−
RVECs; however, a change in the specific activity of APE1/Ref-1 in Vldlr−/− RVECs could
alter sensitivity of these cells to APX3330, and this possibility has not been ruled out at
present. Nevertheless, the high sensitivity of Vldlr−/− RVECs to APX3330 in vitro,
combined with the demonstration in this study that a single intravitreal injection of
APX3330 reduced RAP-like neovascularization in the eyes of Vldlr−/− mice strongly
supports a possible role for APE1/Ref-1 in retinal vascularization.
This study compares and finds significant differences in the effects of APX3330 and
Avastin® on the in vitro properties of RVECs and on RAP-like neovascularization in the
eyes of Vldlr−/− mice. For example, a much higher concentration of Avastin® than
APX3330 was required to reduce CI values of RVECs in vitro, and intravitreal Avastin® did
not reduce RAP-like neovascularization in Vldlr−/− mice, while APX3330 strongly reduced
RAP-like neovascularization after a single intravitreal injection. The weak response to
Avastin® in this model could be due to poor cross-species immunoreactivity with murine
VEGF-A (Yu et al., 2008) and it would require higher dosage. Alternatively, APE-1/Ref1
could be a more effective target than VEGF for inhibiting RVEC viability and proliferation
in vitro (as measured by CI) or reducing RAP-like neovascularization in Vldlr−/− mice
because APE-1/Ref1 is upstream of multiple transcription factors essential for
neovascularization. Also, our data suggest that the effects of APX3330 and Avastin® in
endothelial cell tube formation are additive or synergistic. This is not surprising as
APX3330 blocks APE1/Ref-1 redox function and therefore, would block the ability of
HIF-1α to bind to various downstream target promoters such as VEGF gene and other
angiogenic molecules (Carmeliet et al., 1998, Gariano and Gardner, 2005). Avastin®, on the
other hand, is an antibody that binds to VEGF and prevents it from binding to its target
receptor. While APE1/Ref-1 redox inhibition could affect multiple signaling pathways
including VEGF, and Avastin® neutralizes VEGF molecule turned on by different
mechanisms, these pathways are not necessary overlapping, rather than complementary, to
each other.
In summary, this study suggests that agents such as APX3330, which inhibit APE1/Ref-1
redox activity, have potential as therapeutic agents for treating retinal neovascularization.
APX3330 may be especially useful for treating neovascularization that is refractory to anti-
VEGF agents. The efficacy of APX3330 on choroidal neovascularization is also being
explored for treating neovascular AMD.
• APE1/Ref-1 is expressed in mouse retina, retinal endothelial cells and pericytes.
• APE1/Ref-1 redox inhibition by APX3330 suppresses retinal vascular cell
growth.
• APE1/Ref-1 redox inhibition by APX3330 suppresses retinal vascular cell
growth.
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• APX3330 significantly reduce retinal neovascularization in Vldlr−/− mice.
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In vitro Matrigel Tube Formation. APX3330 inhibits formation of blood-vessel like tubules
in human umbilical cord blood-derived ECFCs. The addition of APX3330 to Avastin®
results in a dramatic decrease in the tube formation ability of these cells at levels much
greater than either agent alone. Avastin® (500 µg/ml) had little effect on tube formation, 10
µM APX3330 reduced tube formation by 61%, and the combination of these two agents at
these doses completely inhibited tube formation. A similar result was observed with
Avastin® (500 µg/ml) and 5 µM APX3330.
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TUNEL (apoptosis) assay performed with various doses of APX3330 on human umbilical
cord ECFCs. Exposure to APX3330 at the dose range between 2.5 to 10 µM for 24 hours
does not induce apoptosis. H2O2 as a positive control agent does induce significant
apoptosis under the condition tested.
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Western analysis of APE1/Ref-1 expression in the retina, RVEC and RPC. High levels of
APE1/Ref-1 protein were detected by a monoclonal anti-APE1/Ref-1 antibody in the retinal
tissue and in purified retinal vascular cells, RVEC and RPC from wild-type (+/+) and
Vldlr−/− (−/−) mice. APE1/Ref-1 expression level was similar in the two mice strains. Anti-
tubulin antibody was used as an internal control. The result is representative of 3 replicates.
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Effects of APX3330 on RVEC proliferation (A) and migration (B). APX3330 inhibited
proliferation of wild-type and Vldlr−/− RVECs in a dose-dependent manner (A). The
inhibition was more potent in Vldlr−/− RVEC than that in wild-type RVEC. APX3330
inhibited the migration of RVECs in a similar fashion. Again, while Vldlr−/− RVEC was
more pro for migration in the control condition, Vldlr−/− RVEC was more sensitive to
APX3330 than wild-type RVEC at the same dosage (B). The effective dosage of APX3330
inhibiting migration (5 µM reduced by ~80–90%) was lower than that for proliferation (10
µM reduced by ~20–40%). *, p < 0.05 when compared with wild-type RVEC normal
control (NC); **, p < 0.05 when compared with Vldlr−/− RVEC NC group; #, p < 0.01
between the two NC groups.
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Matrigel tube formation assay of wild-type (+/+) and Vldlr−/− (−/−) RVECs with or without
various doses of APX3330. A, B, Representative images showing that APX3330 at 20 µM
abolished most of capillary-like structures in Vldlr−/− RVECs (B) comparing to the control
condition without APX3330 treatment (A). C, Quantitative measurement of the number of
tubes showed a striking genotypic difference in the basal level of tube formation with much
more tubules in Vldlr−/− RVECs than those in wild-type RVECs. Nevertheless, addition of
APX3330 was still able to inhibit such profound tube formation dose-dependently. The
inhibition effect on Vldlr−/− RVECs was significant at all doses from 1 to 20 µM of
APX3330. The effects of APX3330 on wild-type RVECs were significant at 10 and 20 µM
of APX3330. *, p < 0.05 when compared with wild-type RVEC NC; **, p < 0.05 when
compared with Vldlr−/− RVEC NC group; #, p < 0.01 between the two NC groups.
Jiang et al. Page 15














Real time analysis of the effect of APX3330 (A, B), Lucentis® (C, D) or Avastin® (E, F) on
wild-type (A, C, E) and Vldlr−/− (B, D, F) RVECs using the xCELLigence system. All
treatment or vehicle control agents were added 2 h after seeding. Cell Index (CI), which
integrally reflects an overall property of endothelial cells including proliferation,
morphology, adhesion, and etc, was monitored and recorded at 30-minute intervals for 72 h.
The administration of APX3330 (5, 10 or 20 µM) significantly reduced CI values in both
wild-type and Vldlr−/− RVECs in a dose- and time-dependent manner (p < 0.05). Despite a
significant upsurge of the growth curve, Vldlr−/− RVECs were quit sensitive to APX3330
(B). The CI value after 20 µM APX3330 treatment in Vldlr−/− RVECs reached a much
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lower level than that of the corresponding dosage in wild-type RVECs. In contrast,
Lucentis® (10 or 100 µg/ml) or Avastin® (50 µg/ml) had little or no effect to RVECs of
both genotypes (p > 0.05). A significant inhibitory effect was only seen at a high dose of 200
µg/ml Avastin® in wild-type and Vldlr−/− RVECs (p < 0.05).
Jiang et al. Page 17














Intravitreal treatment effects of APX3330 or Avastin® on RAP-like neovascularization in
Vldlr−/− mice. At the onset of RAP-like neovascularization (P14), each mouse received a
single intravitreal injection of 1 µl volume of BSS as a vehicle control and the fellow eye
received 1 µl of 200 µm APX3330, or 25 µg Avastin®. Total number of RAP-like
neovascularization was quantified one week after the treatment in the whole mount retina
after isolectin-FITC staining. Representative images of isolectin stained retinal whole mount
showing RAP-like neovascularization spots after BSS control (A) or APX3330 (B)
injection. Quantitative measurement revealed that 17/20 individuals had reduced number of
RAP-like neovascularization in the eyes treated with APX3330 (C). The effective rate is
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85%. The significant improved rate (> 20% reduction) is 75%. Paired t-test analysis showed
a very significant (p = 0.000772) inhibition effect of APX3330 on the total number of RAP-
like neovascularization in Vldlr−/− mice. In contrast, the effect of 25 µg Avastin® treatment
on total number of RAP-like neovascularization was inconsistent (D, p > 0.05).
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